secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2024-12-23T23:59:59+00:00
Accession:  0001193125-24-284214
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanofi terminates losmapimod deal; Fulcrum loses up to $975M in milestones
--------------------------------------------------------------------------

- Sanofi terminated for convenience the May 2024 collaboration for losmapimod (FSHD) effective April 17, 2025.
- Fulcrum received $80M upfront but forfeits all remaining milestones (up to $975M) and tiered royalties.
- Fulcrum no longer entitled to global development cost reimbursement; Phase 3 trial obligations continue until termination.
- After termination, Fulcrum retains full rights to losmapimod but loses ex-U.S. partner and future payments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/0001193125-24-284214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312524284214/d911298d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-284214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer